TG Therapeutics Announces Data Presentations for BRIUMVI® at the 2026 Consortium of Multiple Sclerosis Centers Annual Meeting
TG Therapeutics is presenting four data sets for its approved MS drug BRIUMVI at the 2026 CMSC annual meeting, highlighting positive real-world and observational results. New analyses from the Phase 4 ENABLE study show significant improvements in patient-reported outcomes, with benefits observed as early as Day 15 and sustained through Week 48.
Key figures
- Drug Name
- BRIUMVI (ublituximab-xiiy)
- Relapse free rate
- 99.4%
- Overall infection rate
- 56%
- Serious infection rate
- 5%
- Annualized relapse rate
- 0.011
- Infection related deaths
- 3
- Ultimate trial enrollment
- 1094
- Infusion reaction incidence
- 48%
- Serious infusion reaction rate
- 0.6%
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.